Welcome to our dedicated page for Esperion Therapeutics news (Ticker: ESPR), a resource for investors and traders seeking the latest updates and insights on Esperion Therapeutics stock.
Esperion Therapeutics, Inc. (NASDAQ: ESPR) is a leading pharmaceutical company specializing in the development and commercialization of innovative, first-in-class, oral therapies aimed at lowering low-density lipoprotein cholesterol (LDL-C). The company's flagship product, ETC-1002, is a potent inhibitor of ATP citrate lyase, an enzyme integral to the cholesterol biosynthesis pathway. This pathway also includes HMG-CoA reductase, the enzyme targeted by statins.
Esperion has made significant progress with ETC-1002, completing Phase 1 and Phase 2 clinical trials, and is set to initiate Phase 3 trials. The company's product lineup includes NEXLETOL and NEXLIZET, both of which are oral, once-daily, non-statin medications designed to tackle elevated LDL-C levels. These drugs have recently received expanded FDA approval for cardiovascular risk reduction and are indicated for both primary and secondary prevention patients.
In recent news, Esperion announced that both NEXLETOL and NEXLIZET have received broad new label expansions. These labels now cover cardiovascular risk reduction and expanded LDL-C lowering, either alone or in combination with statins. This approval allows over 70 million patients to access these life-saving drugs, positioning them as the non-statin drugs of choice for cardiovascular risk management.
Esperion is also ramping up its marketing and promotional efforts, enhancing patient support programs, and working with payers to improve patient access. The company is committed to breaking barriers in cardiovascular care and continues to focus on underserved populations, including women and Hispanic/Latinx patients, as demonstrated by their recent CLEAR Outcomes trial.
The company's forward-looking strategy includes ongoing clinical development, financial management, and expansion into new markets. Esperion's dedication to transforming cardiovascular care is evident in its robust pipeline and strategic initiatives aimed at addressing critical unmet medical needs.
Esperion (NASDAQ: ESPR) announced that President and CEO Sheldon Koenig will present at the J.P. Morgan 40th Annual Healthcare Conference on January 13, 2022, at 10:30 a.m. ET. The presentation will include a live audio webcast available on the company's investor relations website, with replays archived for 90 days. Esperion focuses on lipid management, developing innovative medicines to lower cholesterol for patients underserved by existing solutions. More details can be found at www.esperion.com.
Esperion has appointed Benjamin O. Looker as general counsel effective January 1, 2022. Looker brings extensive experience from his previous roles in the pharmaceutical industry, including serving as general counsel at Trillium Therapeutics. His expertise will be critical as Esperion approaches significant milestones, particularly the completion of the CLEAR Outcomes trial and the development of its early-stage pipeline. The leadership believes Looker's guidance will enhance the company's legal, compliance, and ethics operations.
Esperion (NASDAQ: ESPR) has successfully closed its public offering of 32,142,858 shares of common stock and warrants, raising approximately $225 million in gross proceeds. After expenses, net proceeds total around $208.8 million. The underwriter has also partially exercised a 30-day option for additional warrants. The funds will support the commercialization of NEXLETOL and NEXLIZET, as well as research and development efforts. The offering was conducted under a previously filed shelf registration statement with the SEC.
Esperion (NASDAQ: ESPR) has announced a public offering of 32,142,858 shares of common stock, alongside short-term warrants for the same amount, priced at $7.00 each. The offering, set to close on or around December 7, 2021, is expected to generate approximately $225 million in gross proceeds. These funds will be used for commercialization of NEXLETOL and NEXLIZET, pipeline development, and general corporate purposes. The underwriter, H.C. Wainwright & Co., has a 30-day option to purchase an additional 4,821,428 shares or warrants.
Esperion (NASDAQ: ESPR) announced its plan to conduct an underwritten public offering of common stock and warrants, subject to market conditions. The company aims to use the net proceeds for the commercialization of NEXLETOL and NEXLIZET, along with research and development for its pipeline. H.C. Wainwright & Co. will serve as the sole book-running manager for this offering. The offering is subject to various conditions, with no guarantee on its completion or terms. A registration statement has been filed with the SEC, and additional details will be available in a related prospectus.
Esperion announced significant findings from three abstracts on NEXLETOL (bempedoic acid) presented at the AHA Scientific Sessions 2021. Data from pooled Phase 3 studies showed that NEXLETOL effectively lowers LDL-C levels, achieving a ≥30% reduction comparable to high-intensity statins in nearly 1 in 3 patients. In individuals with metabolic syndrome, the treatment resulted in reductions in HbA1c and fasting plasma glucose. Notably, over 50% of patients not on background statins achieved significant LDL-C lowering. This establishes NEXLETOL's role in lipid management.
Esperion (NASDAQ: ESPR) announced a strategic plan to optimize its operational and expense structure, aiming for long-term growth in its lipid management products, NEXLETOL and NEXLIZET. For Q3 2021, U.S. net product revenue reached $10.9 million, driven by a 10% increase in prescriptions, with over 59,200 patients treated. The company reported total revenues of $14.4 million for the quarter, a significant rise from $3.8 million in Q3 2020. Research and development expenses decreased to $25.3 million, while net losses were $69.4 million. Looking ahead, the CLEAR Outcomes study remains on track for completion in 2H 2022.
Esperion (NASDAQ: ESPR) announced the presentation of three abstracts at the American Heart Association (AHA) Scientific Sessions 2021 from November 13-15, 2021. The highlighted studies include:
- Factors Associated with Enhanced LDL Cholesterol Lowering during Phase 3 studies of Bempedoic Acid.
- Efficacy and Safety of Bempedoic Acid in patients with Metabolic Syndrome.
- Pharmacokinetics and Safety of Bempedoic Acid in phase 1 trials.
Bempedoic Acid is indicated for adults requiring additional LDL-C lowering.
Esperion announced the appointment of Seth H.Z. Fischer as a Class III director, with his term expiring at the 2022 stockholders' meeting. His extensive experience in the pharmaceutical industry is expected to aid the company during this transformative period, particularly ahead of the CLEAR Outcomes trial results. Fischer's background includes leadership roles at various pharmaceutical companies, focusing on product growth and market strategies. Esperion aims to enhance access to its cholesterol-lowering oral medications for patients in need.
Esperion (NASDAQ: ESPR) announced participation in the Credit Suisse 30th Annual Healthcare Conference on November 9, 2021. Members of the management team will engage in a fireside chat and 1:1 meetings, scheduled for 4:20 p.m. ET.
Live audio webcasts can be accessed via the Esperion website.
Replays will be available for 90 days after the events.
FAQ
What is the current stock price of Esperion Therapeutics (ESPR)?
What is the market cap of Esperion Therapeutics (ESPR)?
What is Esperion Therapeutics, Inc.?
What products does Esperion offer?
What recent achievements has Esperion made?
What is ETC-1002?
What is the significance of the CLEAR Outcomes trial?
Who can benefit from Esperion's medications?
What partnerships does Esperion have?
What are the common side effects of NEXLETOL and NEXLIZET?
How does Esperion support its patients?
What are Esperion's future plans?
